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E-mail address: azema@tauex.tau.ac.il (A. Azem).Previous studies have shown that the mammalian mitochondrial 70 kDa heat-shock protein (mort-
alin) can also be detected in the cytosol. Cytosolic mortalin binds p53 and by doing so, prevents
translocation of the tumor suppressor into the nucleus. In this study, we developed a novel binding
assay, using puriﬁed proteins, for tracking the interaction between p53 and mortalin. Our results
reveal that: (i) P53 binds to the peptide-binding site of mortalin which enhances the ability of the
former to bind DNA. (ii) An additional previously unknown binding site for mortalin exists within
the C-terminal domain of p53.
Structured summary:
MINT-7557591: p53 (uniprotkb:P04637) binds (MI:0407) to DnaK (uniprotkb:P0A6Y8) by afﬁnity chroma-
tography technology (MI:0004)
MINT-7557644: mortalin (uniprotkb:P38646) binds (MI:0407) to p53 (uniprotkb:P04637) by pull down
(MI:0096)
MINT-7557580, MINT-7557611: p53 (uniprotkb:P04637) binds (MI:0407) tomortalin (uniprotkb:P38646)
by afﬁnity chromatography technology (MI:0004)
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction (3) Mortalin was found to interact with p53 and this interactionThe mitochondrial 70 kDa heat-shock protein (Sscl in yeast and
mortalin in mammals) plays a key role in the biogenesis of mito-
chondrial proteins [1–3]. Several lines of experimental evidence
showed that mortalin performs additional, diverse extra-mito-
chondrial functions [4]. The most apparent evidence for this is
the fact that mortalin has been found to associate with a large
number of unrelated cytosolic proteins. The list includes Mps1 ki-
nase, ﬁbroblast growth factor-1 (FGF-1), cytosolic J proteins, p53
and others (for a review see [5]).
Several observations suggested that mortalin is involved in the
transformation of normal cells to cancer-cells, as well as in the
resistance of cancer-cells to chemotherapy:
(1) Mortalin was found to be overexpressed in tumor cells of
various origins [6].
(2) Mortalin was found to change its subcellular location from
mitochondria, in normal cells, to the cytosol, in cancerous
cells [7].chemical Societies. Published by E
heat-shock protein; PAGE,
erm DNA; FL-p53, full-lengthwas suggested to promote sequestration of p53 in the cyto-
plasm, thereby inhibiting its nuclear activity [5,8,9] and
inducing the resistance of some tumors to radiotherapy
and chemotherapy.
The p53-mortalin interaction has been the subject of several
studies, which mapped the binding sites between mortalin and
p53. For example, one site on p53 that binds mortalin was sug-
gested to be localized to the tetramerization domain, namely amino
acids 323–337 [10]. Conversely, the binding site for p53 onmortalin
was mapped to amino acids 253–282, in the ATPase domain [11].
However, these studies were performed using a combination of
puriﬁed proteins and cell lysates. In this study, we reconstituted
the interaction between p53 and mortalin using puriﬁed proteins
and mapped the domains of interaction between them.
2. Methods
2.1. Cloning and puriﬁcation of proteins
DnaK and mortalin were cloned in bacterial expression vectors
and engineered to carry an octa-histidine tag, which is removable
upon treatment with TEV protease. Proteins were initially puriﬁedlsevier B.V. All rights reserved.
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Superdex 200 gel ﬁltration column.
The p53 used in this study is a super-stable quadruple mutant
form of the protein (M133L/V203A/N239Y/N268D) which is stabi-
lized by the mutations, as described in [12–14]. Full-length super-
stable p53 (residues 1–393) in a modiﬁed pET24a vector, served as
a template for PCR-cloning of the various p53 constructs. P53 con-
structs were puriﬁed using a method previously described [15].
2.2. Pull down of the p53-mortalin complex using heparin-sepharose
beads
Pull-down assays were performed by incubating full-length p53
(FL-p53) or p53 mutants, with the various mortalin constructs. The
proteins were incubated in 200 ll of binding buffer (50 mM Tris–
HCl, pH 7.4, 45 mM KCl, 5 mM MgCl2, 10% glycerol, 5 mM DTT,
1 mg/ml BSA) for 30 min at room temperature. Then, 25 ll of hep-
arin-sepharose beads (Amersham Bioscience) was added to the
reaction and the mixture was incubated at 4 C for 1 h on a rotating
plate. The beads were washed three times with 1 ml of binding
buffer and further incubated at 4 C in elution buffer (binding buf-
fer containing 500 mM KCl) for 30 min. Proteins eluted from the
beads were analyzed using 10% SDS–polyacrylamide gel electro-
phoresis (SDS–PAGE).
2.3. Pull down of the p53-mortalin complex using Nickel-agarose
beads
Proteins were incubated in 200 ll of binding buffer (50 mM
Tris–HCl, pH 7.4, 100 mM KCl, 100 mM NaCl, 5 mMMgCl2, 5% glyc-
erol, 40 mM imidazole, 10 mM b-mercaptoethanol) for 30 min at
room temperature. Then, 15 ll of nickel-agarose beads (GE Health-
care) was added to the reaction and the mixture was incubated at
4 C for 1 h on rotating plate. The beads were washed three times
with 1 ml of binding buffer and further incubated at 4 C in elution
buffer (binding buffer containing 500 mM imidazole) for 30 min.
Proteins eluted from the beads were analyzed on 10% SDS–PAGE.
2.4. Electrophoretic mobility shift assay
The electrophoretic mobility shift assay (EMSA) was carried out
according to a previously published protocol with slight modiﬁca-
tions [16] (see the legend of Fig. S1 for a detailed description).3. Results
3.1. The effect of nucleotides on complex formation between p53 and
mortalin
We developed a new method to track formation of the p53-
mortalin complex and monitor the effect of various co-factors on
the interaction. First, puriﬁed mortalin and p53 are incubated to-
gether to allow for complex formation. It is known that p53 can
bind to heparin-sepharose [17]. Thus, the second step involves
incubating the complex with heparin-sepharose beads, and then
washing the beads three times to remove non-speciﬁcally bound
proteins. P53 and any bound mortalin are eluted from the heparin
beads using 0.5 M KCl and analyzed by SDS–PAGE. The interaction
betweenmortalin and p53 that we detected using the heparin pull-
down assay is speciﬁc since: (i) BSA, which is included in all bind-
ing buffers, did not bind signiﬁcantly either to p53 that was bound
to heparin beads or to heparin beads alone. (ii) Mortalin did not
show signiﬁcant binding to heparin beads, in the absence of p53
(Fig. 1A, lane 2). (iii) A speciﬁc interaction between p53 and the
bacterial homologue of 70-kDa mitochondrial heat-shock protein,DnaK, was also previously reported [18,19]. Consistent with this,
a complex between DnaK and p53 was detected using the heparin
pull-down assay (Fig. 1B).
The interaction between Hsp70 chaperones and their client pro-
teins is modulated by nucleotides. Thus, we examined the effect of
nucleotides on the p53-mortalin interaction. Without added nucle-
otides, a very strong association was observed between mortalin
and p53. Strong complex formation was also observed in the pres-
ence of ADP. In contrast, in the presence of ATP, the p53-mortalin
complex did not form at all. Dissociation of the p53-mortalin com-
plex was also observed in the presence of AMP-PNP, a non-hydro-
lyzable analogue of ATP, albeit less than in the presence of ATP
(Fig. 1A). Notably, a similar effect of various nucleotides was also
observed when we examined the DnaK-p53 interaction (Fig. 1B).
In summary, we were able to observe an interaction between puri-
ﬁed p53 and mortalin using the method of pull-down with hepa-
rin-sepharose beads. The interaction is sensitive to the presence
of nucleotides. As such, the p53-mortalin complex was found to
partially dissociate in the presence of AMP-PNP and completely
in the presence of ATP.
3.2. P53 binds directly to the peptide-binding site of mortalin
The aforementioned method enabled us to examine directly
which domain of mortalin – the ATP-binding or peptide-binding
domain – associates with p53. For this purpose, we expressed
the ATP-binding and the peptide-binding domains of mortalin
individually in bacteria and puriﬁed them. Next, we carried out
the heparin pull-down assay, as previously described. Interest-
ingly, we found that the peptide-binding domain (Fig. 2B, lanes
3–8), but not the ATP-binding domain (Fig. 2B, lane 11), was able
to associate with p53, in a concentration dependent manner. These
results are in contrast to results obtained using cell lysates, which
suggested that the association of p53 occurs via the ATP-binding
domain of mortalin [11]. We next examined whether the associa-
tion of mortalin with p53 is affected by mutating the peptide-bind-
ing region of mortalin. To this end, we created a mutant of
mortalin, V482F, which is expected to exhibit a defective interac-
tion with substrate proteins, based on a similar DnaK mutant
[20]. Indeed, the V482F mutant of mortalin did not bind p53 at
all, when examined using the heparin-binding assay (Fig. 2C). Fi-
nally, when mortalin was preincubated with p5, a peptide that
was shown to bind strongly to Hsp70 chaperones [21], binding of
p53 was signiﬁcantly reduced (Fig. S2). We conclude that puriﬁed
p53 binds puriﬁed mortalin via its peptide-binding site, through an
interaction that is sensitive to the presence of nucleotides.
3.3. Mortalin binding affects the ability of p53 to bind DNA
Chaperone proteins were shown to affect the ability of p53 to
bind DNA [18,22,23]. Such an effect of mortalin on p53 was never
demonstrated. Consequently, the next step was to examine the
ability of p53 to bind radio-labeled DNA using an Electrophoretic
Mobility Shift Assay (EMSA). As shown in Fig. 3, p53 alone binds
DNA. In agreement with previous reports, which demonstrated
that the C-terminal region of p53 plays an important role as a reg-
ulator of speciﬁc DNA binding by the protein, association was dra-
matically increased upon deletion of the C-terminal domain of the
protein (p53DCTD) (Fig. 4A) [18]. Addition of excess, non-speciﬁc,
unlabeled DNA as binding competition decreased the binding of
double-stranded radio-labeled DNA by p53. Interestingly, a pro-
found increase in the ability of p53 to bind DNA was observed
when mortalin was included in the reaction mixture (Fig. 3, lane
11). When binding was examined in the presence of the V482F mu-
tant of mortalin, the speciﬁc DNA binding by p53 was 63% less
than binding in the presence of wild type mortalin (Fig. S1). The
Fig. 1. Effect of nucleotides on the p53-mortalin interaction. FL-p53 was subjected to the heparin-bead pull-down assay (see Section 2) in the presence of (A) Mortalin or (B)
DnaK, together with various nucleotides (1 mM) as indicated. The concentration of all proteins in all the reactions was 10 lM.
Fig. 2. P53 binds to the substrate-binding domain of mortalin. (A) Schematic representation of mortalin constructs used in this study. Constructs that bind to p53 are
designated with a ‘‘+” to the right of the panel. In B and C, the heparin-bead pull-down assay was carried out as described under Section 2. (B) 5 lg of SBD (lane 1) and 2.5 lg
of the ATPase domain (lane 2). Lanes 3–8 correspond to 10, 20, 40, 60, 80, and 100 lM SBD, that was incubated with FL-p53 (10 lM). In lane 9, FL-p53 was incubated with
10 lM of mortalin. Lane 10: 10 lM of SBD were incubated with heparin beads alone. Lane 11: FL-p53 was incubated with 40 lM of the ATPase domain. (C) FL-p53 (10 lM)
was incubated with the indicated concentrations of mortalin or mortalin-V482F.
Fig. 3. Mortalin affects the ability of p53 to bind DNA. EMSA was carried out as
described in the legend to Fig. S1. Protein concentrations were 0.1 mg/ml for the
indicated p53 constructs and 2 mg/ml for mortalin constructs.
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p53 (Fig. S1) suggests that the mutation did not completely abolish
an interaction between the two. This interaction was not observed
in the heparin-binding experiments due to the extensive washes
used in our binding assay (Fig. 2C). In summary, we have demon-
strated for the ﬁrst time that mortalin regulates the ability of
p53 to bind DNA.
3.4. P53 harbors two distinct binding sites for mortalin
Our successful reconstitution of the interaction between p53
and mortalin from puriﬁed components enabled us to examine
the binding site for mortalin on p53. To this end, we investigated
the ability of several modiﬁed p53 constructs to bind puriﬁed
mortalin (Fig. 4A). The ﬁrst was a deletion of the C-terminal do-
main (CTD) which was previously shown to bind DnaK and other
Hsp70 family members [18,24]. Notably, deletion of this region
did not abolish the ability of p53 to bind mortalin (Fig. 4B). Another
Fig. 4. Two sites for mortalin binding on p53. (A) Schematic representation of the various p53 constructs used in this study. Constructs that bind to mortalin are designated
with a ‘‘+” to the right of the panel. In B, C and E, the heparin-beads pull-down assay was carried out as described under Section 2. When included, the p53 concentration was
10 lM. (B) The indicated mortalin concentrations were incubated with either p53DCTD (lanes 1–5) or with FL-p53 (lanes 6–10). (C) Lanes 1–3: FL-p53, p53DTET and 20 lM
mortalin were incubated alone with heparin beads, respectively. Lane 4: incubation of FL-p53 with 10 lM of mortalin. Lanes 5–7: the indicated mortalin concentrations were
incubated with p53DTET. (D) A Nickel-bead pull-down assay was carried out as described under Section 2. Lane 1: 10 lM of mortalin-his8 were incubated alone with nickel
beads. Lanes 2–4: 10 lM of either p53DCT, p53NLS or p53 DCTD were incubated alone with nickel beads, respectively. Lanes 5–7 correspond to 10 lM of mortalin-his8 that
were incubated with 10 lM of either p53DCT, p53NLS or p53DCTD, respectively. Lane 8: 5 lg of p53DCTD. Lane 9: 5 lg of p53DCT and p53NLS. (E) p53-L344P was incubated
with either 10 lM of mortalin (lane 1) or mortalin-V482F (lane 2) and protein complexes were subjected to the heparin pull-down assay.
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be the region mediating interaction with mortalin [10]. Interest-
ingly, a puriﬁed construct of p53 that harbors a deletion of the
TET domain was also able to bind mortalin (Fig. 4C). These results
suggest that p53 harbors two binding sites for mortalin, one in the
TET domain and the second in the CTD. To examine this possibility,
we designed and puriﬁed two additional constructs, both of which
lack the TET domain and the CTD. The ﬁrst is p53NLS, which con-
tains the nuclear localization signal (NLS) area (a.a. 292–325) and
the second is p53DCT which additionally lacks the NLS domain
[25]. In contrast to full-length p53, puriﬁed p53NLS and p53DCT
did not bind to heparin beads and did not bind non-speciﬁcally
to Ni-agarose beads (not shown). Thus, we used octa-histidine
tagged mortalin to examine its binding to puriﬁed p53NLS and
p53DCT by pull-down experiments with Ni-agarose. As shown inFig. 4D, neither puriﬁed p53NLS nor p53DCT bound to mortalin
in the Ni-agarose pull-down assay. As a positive control, we used
p53DCTD, which bound mortalin in the heparin-sepharose assay
(Fig. 4B), and did not bind to Ni-agarose in a non-speciﬁc manner
(Fig. 4D, lane 4). As expected, from the heparin pull-down experi-
ments, p53DCTDwas detected bound to mortalin using the Ni-aga-
rose pull-down assay (Fig. 4D, lane 7). All together, these results
suggest that p53 harbors two binding sites for mortalin, one in
the C-terminal domain and the other in the TET domain. Each
one of these domains is sufﬁcient to allow binding of mortalin to
p53. In a ﬁnal experiment, we examined whether the tetrameric
structure of p53 is necessary for binding mortalin. To examine this
possibility, we created a mutant of p53 (L344P) that was previously
shown to be impaired in its ability to form tetramers [26]. Puriﬁed
p53 (L344P) was able to bind mortalin similarly to the wild type
1084 O. Iosefson, A. Azem / FEBS Letters 584 (2010) 1080–1084protein (Fig. 4E). We conclude that the tetrameric structure of p53
is not required for its association with mortalin.
4. Discussion
P53 is a tumor suppressor that is essential for the prevention of
cancer development [27]. This function of p53 requires that it be
translocated to the nucleus. Factors preventing the movement of
p53 into the nucleus should therefore prevent its anti-tumor func-
tion and thereby enhance cancer development [28–31]. Mitochon-
drial localization and interaction of p53 have been also reported
[32]. Mortalin was shown to bind p53 in the cytosol and was sug-
gested to prevent its translocation into the nucleus [7]. In this
study, we developed a pull-down assay using heparin beads to
map domains that mediate the p53-mortalin interaction. We
showed that (i) p53 binds to the peptide-binding domain of mort-
alin and not to the ATP-binding site as previously reported [11].
Our results are in accord with previous results showing that
Hsp70 chaperones bind p53 as a substrate protein [23]. (ii) P53
harbors two binding sites for mortalin. The ﬁrst one was previously
determined to be in the tetramerization domain [10], and the sec-
ond is found in the C-terminal domain. Interestingly, the binding
site for DnaK was also shown to be in the CTD [19]. The differences
between the results of this in vitro study and the results of previous
studies may be explained by possible modiﬁcation or additional
interacting proteins which may exist in cell lysates and may affect
the character of the interaction between p53 and mortalin. Further
study will be required to determine which of these possibilities is
the case.
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